Elicio Therapeutics, Inc. announced financial results for the year ended December 31, 2025, reporting R&D expense of $24.9 million, G&A expense of $12.8 million, and net loss of $39.5 million. The company provided updates on the Phase 2 AMPLIFY-7P trial, with event-driven primary DFS analysis anticipated in 1H 2026, and cash runway into Q3 2026.
Key takeaways
Net loss for 2025 was $39.5 million vs $51.9 million for 2024
R&D expense for 2025 was $24.9 million vs $33.7 million for 2024
G&A expense for 2025 was $12.8 million vs $11.3 million for 2024
Net loss per share for 2025 was $2.58 vs $4.25 for 2024
Cash and cash equivalents as of December 31, 2025 were $18.6 million
Event-driven primary DFS analysis for Phase 2 AMPLIFY-7P trial anticipated in 1H 2026
Raised net proceeds of $4.9 million in Q4 2025 and $6.3 million in Q1 2026 via at-the-market program